Articles related to HORMONE REPLACEMENT THERAPY (HRT)

An AJN editorial highlights confusion surrounding perimenopause symptoms and gaps in clinician education, drawing on published research and personal experience rather than presenting new diagnostic or treatment evidence.

Conference presenters highlighted gaps in menopause medication coverage and follow-up support, describing opportunities for pharmacist involvement while offering no comparative evidence that employer-sponsored programs improve symptoms, adherence, or workplace outcomes.

Small observational studies linked menopausal hormone therapy with improvements in cognitive and mood symptoms, while a large meta-analysis found no overall dementia association, leaving cognitive treatment benefits insufficiently established.

A menopause-associated blood protein pattern was linked to poorer cognition and Alzheimer’s disease in older women across observational cohorts. Replication supports research interest, but the findings do not establish causality, individual prediction, or hormone-therapy prevention benefits.

Healthline reports that updated ACOG guidance strongly supports hormone therapy for vasomotor symptoms and related sleep disturbance in eligible patients. Nonhormonal options also receive strong recommendations; evidence remains insufficient for hormone therapy targeting depressive symptoms.

ACP places estrogen-based therapy first in its pharmacologic pathway for menopausal vasomotor symptoms, with nonhormonal alternatives for contraindications or intolerance. Recommendation strength and evidence certainty vary, and long-term safety evidence remains limited.